

Short Note

(2E)-3-(3,5-Dimethyl-1-phenyl-1H-pyrazol-4-yl)-1-(2,5-dimethyl-3-thienyl)prop-2-en-1-one

Abdullah M. Asiri ^{1,2,*} and Salman A. Khan ¹

¹ Chemistry Department, Faculty of Science, King Abdul Aziz University, P.O. Box 80203, Jeddah, Saudi Arabia

² The Center of Excellence for Advanced Materials Research, King Abdul Aziz University, Jeddah, P.O. Box 80203, Saudi Arabia

* Author to whom correspondence should be addressed; E-Mail: aasiri2@kau.edu.sa; Tel.: +966 2 6952293; Fax: +966 2 6952292.


Received: 30 March 2010 / Accepted: 22 April 2010 / Published: 27 April 2010

Abstract: The title compound, (2E)-3-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-yl)-1-(2,5-dimethyl-3-thienyl)prop-2-en-1-one (**3**) was synthesized in high yield by aldol condensation of 3-acetyl-2,5-dimethylthiophene and 3,5-dimethyl-1-phenylpyrazole-4-carboxaldehyde in ethanolic NaOH at room temperature. Its structure was fully characterized by elemental analysis, IR, ¹H NMR, ¹³C NMR and EI-MS spectral analysis.

Keywords: chalcone; aldol condensation; 3-acetyl-2,5-dimethylthiophene

Chalcones are open-chain flavonoids with a common skeleton of 1,3-diaryl-2-propen-1-one [1]. They possess a wide range of biological activities such as antioxidant [2], antibacterial [3], antidepressant [4], antihypertensive [5] and anti-inflammatory activity [6]. Transformation of chalcones into pyrazoline derivatives can dramatically increase their biological properties such as antibacterial [7], antiprotozoal [8], or anti-inflammatory [9] activities. On the basis of these aspects we have synthesized a novel pyrazoline-based chalcone from 3-acetyl-2,5-dimethylthiophene and 3,5-dimethyl-1-phenylpyrazole-4-carboxaldehyde.

Figure 1. Synthesis of compound 3.



A solution of 3-acetyl-2,5-dimethylthiophene (0.38 g, 0.0025 mol) and 3,5-dimethyl-1-phenylpyrazole-4-carboxaldehyde (0.50 g, 0.0025 mol) in an ethanolic solution of NaOH (6.0 g in 10 mL of ethanol) was stirred for 16 h at room temperature. The solution was poured into ice-cold water of pH ~ 2 (pH adjusted by HCl). The solid was separated and dissolved in CH₂Cl₂, this solution was washed with a saturated solution of NaHCO₃ and then evaporated to dryness. The residue was recrystallized from methanol/chloroform.

Light-yellow solid: yield: 78%; m.p. 111–112 °C.

EI-MS m/z (rel. int.%): 337 (65) [M+1]⁺,

IR (KBr) ν_{\max} cm⁻¹: 3055 (Ar-H), 2918 (C-H), 1642 (C=O), 1575 (C=C).

¹H NMR (DMSO-*d*₆) (δ/ppm): 7.71 (d, 1H, $J = 16.2$ Hz, 8-CH), 7.35 (d, 1H, $J = 16.0$ Hz, 7-CH), 7.19 (s, 1H, thiophene 4-H), 7.24–6.93 (m, 5H, Ph), 2.65 (s, 3H, pyrazole 3-CH₃), 2.44 (s, 3H, pyrazole 5-CH₃), 2.37 (s, 3H, thiophene 2-CH₃), 2.36 (s, 3H, thiophene 5-CH₃).

¹³C NMR (150 MHz, CDCl₃) δ: 185.43 (CO), 150.79 (10-C), 145.59, 140.04, 137.90, 136.00, 134.25, 133.86, 128.32, 127.74, 124.82, 123.89, 117.92, 114.32, 28.67, 14.92, 13.94, 11.96, 10.62.

Anal. calc. for C₂₀H₂₀N₂OS: C, 71.40, H, 5.99, N, 8.33. Found: C, 71.36, H, 5.95, N, 8.28.

Acknowledgements

The authors would like to thank the Chemistry Department, King Abdul Aziz University, Jeddah, Saudi Arabia for providing the research facilities and the deanship of scientific research for the financial support of this work via Grant No. (3-045/430).

References and Notes

- Batovska, D.; Parushev, S.; Stamboliyska, B.; Tsvetkova, I.; Ninova, M.; Najdenski, H. Examination of growth inhibitory properties of synthetic chalcones for which antibacterial activity was predicted. *Eur. J. Med. Chem.* **2009**, *44*, 2211–2218.

2. Bandgar, B.P.; Gawande, S.S. Synthesis and biological screening of a combinatorial library of β -chlorovinyl chalcones as anticancer, anti-inflammatory and antimicrobial agents. *Bior. Med. Chem.* **2010**, *18*, 2060–2065.
3. Nielsen, S.F.; Boesen, T.; Larsen, M.; Schonning, K.; Kromann, H. Antibacterial chalcones – bioisosteric replacement of the 4'-hydroxy group. *Bioorg. Med. Chem.* **2004**, *12*, 3047–3054.
4. Ozdemir, Z.; Kandilci, H.B.; Gumusel, B.; Calis, U.; Bilgin, A.A. Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives. *Eur. J. Med. Chem.* **2007**, *42*, 373–379.
5. Ansari, F.L.; Iftikhar, F.; Ihsan-ul-Haq; Mirza, B.; Baseer, M.; Rashid, U. Solid-phase synthesis and biological evaluation of a parallel library of 2,3-dihydro-1,5-benzothiazepines. *Bioorg. Med. Chem.* **2008**, *16*, 7691–7697.
6. Asiri, A.M.; Khan, S.A. (2*E*,2'*E*)-3,3-(1,4-Phenylene)bis[1-(2,5-dimethyl-3-thienyl)prop-2-en-1-one]. *Molbank* **2009**, 2009, M636.
7. Holla, B.S.; Akberali, P.M.; Shivananda, M.K. Studies on arylfuran derivatives: Part X. Synthesis and antibacterial properties of arylfuryl- Δ^2 -pyrazolines. *Il Farmaco* **2000**, *55*, 256–263.
8. Chimenti, F.; Bizzarri, B.; Manna, F.; Bolasco, A.; Secci, D.; Chimenti, P.; Granese, A.; Rivanera, D.; Lilli, D.; Scaltrito, M.M.; Brenciaglia, M.I. Synthesis and in vitro selective anti-*Helicobacter pylori* activity of pyrazoline derivatives. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 603–607.
9. Manna, F.; Chimenti, F.; Bolasco, A.; Cenicola, M.L.; Amico, M.D.; Parrillo, C.; Rossi, F.; Marmo, E. Anti-inflammatory, analgesic and antipyretic N-acetyl- Δ^2 -pyrazolines and dihydrothienocoumarines. *Eur. J. Med. Chem.* **1992**, *27*, 633–639.

© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).